Quick Answer
Tvardi Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $7.14 million for the year ending 2024.
- Tvardi Therapeutics, Inc. showed a decrease of -66.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2025.
- XBRL data for this metric is available from 2016 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $2.87 million | Q3 2018: $5.06 million | Q4 2018: $5.53 million | Q1 2019: $4.38 million | Q2 2019: $5.21 million | Q3 2019: $5.79 million | Q4 2019: $4.51 million | Q1 2020: $8.09 million | Q2 2020: $5.63 million | Q3 2020: $9.27 million | Q4 2020: $112.09 million | Q1 2021: $1.94 million | Q3 2021: $20.27 million | Q1 2022: $4.79 million | Q2 2022: $23.00 million | Q3 2022: $10.81 million | Q1 2023: $6.17 million | Q2 2023: $6.93 million | Q3 2023: $4.87 million | Q1 2024: $2.14 million | Q2 2024: $991.0 thousand | Q3 2024: $2.56 million | Q1 2025: $2.57 million.
- Over the full 9 years of available data (2016 to 2024), Tvardi Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 8,198.8%.
- Historical annual values: Fiscal year 2024: $7.14 million | Fiscal year 2023: $20.97 million | Fiscal year 2022: $41.87 million | Fiscal year 2021: $23.03 million | Fiscal year 2020: $135.08 million | Fiscal year 2019: $19.89 million | Fiscal year 2018: $13.47 million | Fiscal year 2017: $911.0 thousand | Fiscal year 2016: $86.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: